← Back to Search

Sodium Channel Blocker

Ranolazine for Angina (REPTAR Trial)

Phase 4
Waitlist Available
Research Sponsored by Amit Malhotra, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights

REPTAR Trial Summary

The post-marketing study is designed to evaluate the activity level and exercise tolerance of patients with deferred percutaneous intervention due to FFR (fractional flow reserve) greater or equal to 0.81 and treatment with Ranolazine versus placebo.

Eligible Conditions
  • Angina

REPTAR Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Within-patient comparison of accelerometer-assessed physical activity utilizing the Actigraph accelerpmeter from baseline to end of study between Ranolazine and placebo.

REPTAR Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: RanolazineActive Control1 Intervention
At randomization, patients will be started on 500mg of Ranolazine, twice daily for 1 week. After 1 week, the dosage may be increased to 1000mg of Ranolazine, twice daily for 5 weeks.
Group II: PlaceboPlacebo Group1 Intervention
At Randomization, patients will be started on 500mg of a placebo, twice daily for 1 week. After 1 week, the dosage of the placebo may be increased to 1000mg, twice daily for 5 weeks.

Find a Location

Who is running the clinical trial?

Amit Malhotra, MDLead Sponsor
Gilead SciencesIndustry Sponsor
1,084 Previous Clinical Trials
848,222 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
New England Journal of MedicineJournal
Fractional Flow Reserve Versus Angiography for Guiding Percutaneous Coronary Intervention
Tonino, Pim A.L., Bernard De Bruyne, Nico H.J. Pijls, Uwe Siebert, Fumiaki Ikeno, Marcel van `t Veer, Volker Klauss, et al.. 2009. “Fractional Flow Reserve Versus Angiography for Guiding Percutaneous Coronary Intervention”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmoa0807611.
clinicaltrials.govStudy
Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR)
Amit Malhotra, MD 2017. "Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03044964.
All > Ranolazine
~5 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top